Alterola Biotech Stock Price To Book
| ABTI Stock | USD 0 0.0001 2.44% |
Alterola Biotech fundamentals help investors to digest information that contributes to Alterola Biotech's financial success or failures. It also enables traders to predict the movement of Alterola Pink Sheet. The fundamental analysis module provides a way to measure Alterola Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alterola Biotech pink sheet.
Alterola |
Alterola Biotech Company Price To Book Analysis
Alterola Biotech's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Alterola Biotech Price To Book | 6.29 X |
Most of Alterola Biotech's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alterola Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Based on the latest financial disclosure, Alterola Biotech has a Price To Book of 6.2902 times. This is 75.51% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The price to book for all United States stocks is 33.86% higher than that of the company.
Alterola Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alterola Biotech's direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Alterola Biotech could also be used in its relative valuation, which is a method of valuing Alterola Biotech by comparing valuation metrics of similar companies.Alterola Biotech is currently under evaluation in price to book category among its peers.
Alterola Fundamentals
| Return On Equity | -1.27 | |||
| Return On Asset | -0.67 | |||
| Current Valuation | 68.08 M | |||
| Shares Outstanding | 807.05 M | |||
| Price To Book | 6.29 X | |||
| EBITDA | (6.47 M) | |||
| Net Income | (6.47 M) | |||
| Cash And Equivalents | 61.54 K | |||
| Total Debt | 251.18 K | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 0.10 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | 44.34 K | |||
| Earnings Per Share | (0.01) X | |||
| Beta | -6.65 | |||
| Market Capitalization | 39.55 M | |||
| Total Asset | 12.13 K | |||
| Net Asset | 12.13 K |
About Alterola Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alterola Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alterola Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alterola Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Alterola Pink Sheet
Alterola Biotech financial ratios help investors to determine whether Alterola Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Alterola with respect to the benefits of owning Alterola Biotech security.